Work

Phase II study of pembrolizumab in docetaxel-pretreated patients with metastatic castration-resistant prostate cancer (mCRPC): Updated follow-up of cohorts (C) one to three from KEYNOTE-199.

Year: 2020

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2020.38.15_suppl.e17584

Authors: Jeffrey C. Goh, Jose Maria M. Piulats Rodriguez, Marine Gross-Goupil, Ulka N. Vaishampayan, Ronald De Wit, Tuomo Alanko, Satoshi Fukasawa, Kenichi Tabata, Susan Feyerabend, Raanan Berger, Haiyan Wu, Jeri Kim, Charles Schloss, Johann S. De Bono, Emmanuel S. Antonarakis

Institutions: Royal Brisbane and Women's Hospital, Institut Català d'Oncologia, Duran i Reynals Hospital, Institut Bergonié, Wayne State University, The Barbara Ann Karmanos Cancer Institute, Erasmus MC, Docrates Cancer Center, Chiba Cancer Center, Kitasato University, Sheba Medical Center, Merck & Co., Inc., Rahway, NJ, USA (United States), Royal Marsden NHS Foundation Trust, Royal Marsden Hospital, Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3029974225

Cites:

Cited by: 1

Related to: 10